Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology

Lancet Oncology

Volumn 8, Issue 12, 2007, Pages 1101-1115

  Wildiers, Hans ^a   Kunkler, Ian ^b   Biganzoli, Laura ^c   Fracheboud, Jacques ^d   Vlastos, George ^e   Bernard Marty, Chantal ^f   Hurria, Arti ^g   Extermann, Martine ^h   Girre, Véronique ⁱ   Brain, Etienne ^j   Audisio, Riccardo A ^k   Bartelink, Harry ^l   Barton, Mary ^m   Giordano, Sharon H ⁿ   Muss, Hyman ^o   Aapro, Matti ^p  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f JULES BORDET INSTITUTE   (Belgium)

^g Division of Medical Oncology   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ INSTITUT CURIE   (France)

^j Medical Oncology   (France)

^k UNIVERSITY OF LIVERPOOL   (United Kingdom)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o UNIVERSITY OF VERMONT   (United States)

^p CLINIQUE DE GENOLIER   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GESTAGEN; LETROZOLE; METHOTREXATE; NAVELBINE; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID;

AGED; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; MEDLINE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 36549075573     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70378-9     Document Type: Review

References (149)

1. Ferlay J., Bray F., Pisani P., and Parkin D. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0 (2004), IARCPress GLOBOCAN, Lyon
2. Althuis M., Dozier J., Anderson W., Devesa S., and Brinton L. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34 (2005) 405-412
3. Parkin D., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
4. Diab S., Elledge R., and Clark G. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92 (2000) 550-556
5. Gennari R., Curigliano G., Rotmensz N., et al. Breast carcinoma in elderly women-features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 101 (2004) 1302-1310
6. Singh R., Hellman S., and Heimann R. The natural history of breast carcinoma in the elderly-implications for screening and treatment. Cancer 100 (2004) 1807-1813
7. Ballard-Barbash R., Potosky A., Harlan L., Nayfield S., and Kessler L. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 88 (1996) 716-726
8. Joslyn S. Radiation therapy and patient age in the survival from early-stage breast cancer. Int J Radiat Oncol Biol Phys 44 (1999) 821-826
9. Tyldesley S., Zhang-Salomons J., Groome P., et al. Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 47 (2000) 469-480
10. Bouchardy C., Rapiti E., Fioretta G., et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21 (2003) 3580-3587
11. Giordano S., Hortobagyi G., Kau S., Theriault R., and Bondy M. Breast cancer treatment guidelines in older women. J Clin Oncol 23 (2005) 783-791
12. Yancik R., Wesley M., Ries L., Havlik R., Edwards B., and Yates J. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285 (2001) 885-892
13. Goodwin J., Hunt W., Humble C., Key C., and Samet J. Cancer treatment protocols. Who gets chosen?. Arch Intern Med 148 (1988) 2258-2260
14. Kemeny M., Peterson B., Kornblith A., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21 (2003) 2268-2275
15. Townsley C., Selby R., and Siu L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23 (2005) 3112-3124
16. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
17. Louwman W., Janssen-Heijnen M., Houterman S., et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41 (2005) 779-785
18. Walter L., and Covinsky K. Cancer screening in elderly patients-a framework for individualized decision making. JAMA 285 (2001) 2750-2756
19. Satariano W. Aging, comorbidity, and breast cancer survival: an epidemiologic view. Adv Exp Med Biol 330 (1993) 1-11
20. Pierga J., Girre V., Laurence V., et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 13 (2004) 369-375
21. Humphrey L., Helfand M., Chan B., and Woolf S. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (2002) 347-360
22. Vainio H., and Bianchini F. Breast cancer screening. IARC handbooks of cancer prevention volume 7 (2002), IARC Press, Lyon
23. Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjold B., and Rutqvist L. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 (2002) 909-919
24. Galit W., Green M., and Lital K. Routine screening mammography in women older than 74 years: a review of the available data. Maturitas 57 (2007) 109-119
25. Fracheboud J., Groenewoud J., Boer R., et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 118 (2006) 2020-2025
26. Walter L., Lewis C., and Barton M. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 118 (2005) 1078-1086
27. AGS Ethics Committee. AGS position paper: health screening decisions for older adults. http://www.americangeriatrics.org/products/poitionpapers/stopscreeningPF.shtml (accessed Dec 24, 2004).
28. AGS Clinical Practice Committee. American Geriatrics Society (AGS) position statement: breast cancer screening in older women. http://www.americangeriatrics.org/staging/products/poitionpapers/brstcncrPF.shtml (accessed Dec 24, 2004).
29. Smith R., Cokkinides V., and Eyre H. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin 54 (2004) 41-52
30. Gennari R., Rotmensz N., Perego E., dos S., and Veronesi U. Sentinel node biopsy in elderly breast cancer patients. Surg Oncol 13 (2004) 193-196
31. Audisio R. The surgical risk of elderly patients with cancer. Surg Oncol 13 (2004) 169-173
32. Tan L., and Guenther J. Outpatient definitive breast cancer surgery. Am Surg 63 (1997) 865-867
33. Najarian M., Johnson J., Landercasper J., Havlik P., Lambert P., and McCarthy D. Paravertebral block: an alternative to general anesthesia in breast cancer surgery. Am Surg 69 (2003) 213-218
34. Rai S., and Stotter A. Management of elderly patients with breast cancer: the time for surgery. Anz J Surg 75 (2005) 863-865
35. Fentiman I., Christiaens M., Paridaens R., et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 39 (2003) 309-316
36. Robertson J., Todd J., Ellis I., Elston C., and Blamey R. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ 297 (1988) 511-514
37. Gazet J., Ford H., Coombes R., et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20 (1994) 207-214
38. Mustacchi G., Ceccherini R., Milani S., et al. Tamoxifen alone versus adjuvant tamoxifen or operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14 (2003) 414-420
39. van Dalsen A., and de Vries J. Treatment of breast cancer in elderly patients. J Surg Oncol 60 (1995) 80-82
40. Fennessy M., Bates T., MacRae K., Riley D., Houghton J., and Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 91 (2004) 699-704
41. Hind D., Wyld L., Beverley C., and Reed M. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 1 (2006) CD004272.
42. Smith I., Dowsett M., Ebbs S., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
43. Ellis M., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
44. Buzdar A. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview. J Steroid Biochem Mol Biol 86 (2003) 399-403
45. Hurria A., Leung D., Trainor K., Borgen P., Norton L., and Hudis C. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 46 (2003) 121-126
46. De Haes J., Curran D., Aaronson N., and Fentiman I. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer 39 (2003) 945-951
47. Sandison A., Gold D., Wright P., and Jones P. Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg 83 (1996) 994-996
48. Recht A., Come S., Henderson I., et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334 (1996) 1356-1361
49. Vandongen J., Bartelink H., Fentiman I., et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer-Eortc Trial-10801, breast conservation compared with mastectomy in TNM stage-I and stage-II breast cancer. Eur J Cancer 28A (1992) 801-805
50. Veronesi U., Salvadori B., Luini A., et al. Breast conservation is a safe method in patients with small cancer of the breast-long-term results of 3 randomized trials on 1,973 patients. Eur J Cancer 31A (1995) 1574-1579
51. DiBiase S., Komarnicky L., Schwartz G., Xie Y., and Mansfield C. The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma. Cancer 82 (1998) 2212-2220
52. Park C., Mitsumori M., Nixon A., et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18 (2000) 1668-1675
53. Smitt M., Nowels K., Zdeblick M., et al. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 76 (1995) 259-267
54. Gage I., Schnitt S., Nixon A., et al. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 78 (1996) 1921-1928
55. Jones H., Antonini N., Hart G., et al. Significance of margins of excision on breast cancer recurrence (on behalf of the EORTC Radiotherapy, Breast Cancer Groups). Eur J Cancer 2 (2004) (abstr 316).
56. Litvak D., and Arora R. Treatment of elderly, breast cancer patients in a community hospital setting. Arch Surg 141 (2006) 985-990
57. Hack T., Cohen L., Katz J., Robson L., and Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 17 (1999) 143-149
58. Mandelblatt J., Edge S., Meropol N., et al. Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol 21 (2003) 855-863
59. Yap K., McCready D., Narod S., Manchul L., Trudeau M., and Fyles A. Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma. Cancer 97 (2003) 1369-1375
60. Martelli G., Miceli R., De Palo G., et al. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?. Cancer 97 (2003) 1156-1163
61. Martelli G., Boracchi P., De Palo M., et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer-results after 5 years of follow-up. Ann Surg 242 (2005) 1-6
62. Truong P., Bernstein V., Wai E., Chua B., Speers C., and Olivotto I. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Int J Radiat Oncol Biol Phys 54 (2002) 794-803
63. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349 (2003) 546-553
64. Holmberg S., Crivellari D., Zahrieh D., et al. A randomized trial comparing axillary clearance versus no axillary clearance in older patients (=60 years) with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. Proc Am Soc Clin Oncol 22 (2004) (abstr 505).
65. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 339 (1998) 941-946
66. McMahon L., Gray R., and Pockaj B. Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond?. Am J Surg 190 (2005) 366-370
67. Kuerer H., Newman L., Smith T., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
68. Veronesi U., Orecchia R., Zurrida S., et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 16 (2005) 383-388
69. Lyman G., Giuliano A., Somerfield M., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
70. Van Zee K., Manasseh D., Bevilacqua J., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10 (2003) 1140-1151
71. Huguenin P., Glanzmann C., and Lutolf U. Acute toxicity of curative radiotherapy in elderly patients. Strahlenther Onkol 172 (1996) 658-663
72. Wyckoff J., Greenberg H., Sanderson R., Wallach P., and Balducci L. Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc 42 (1994) 150-152
73. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
74. The Uppsala-Orebro Breast Cancer Study Group. Sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Natl Cancer Inst 82 (1990) 277-282
75. Clark R., Mcculloch P., Levine M., et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84 (1992) 683-689
76. Clark R., Whelan T., Levine M., et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst 88 (1996) 1659-1664
77. Liljegren G., Holmberg L., Adami H., et al. Sector resection with or without postoperative radiotherapy for stage-I breast cancer-5-year results of a randomized trial. J Natl Cancer Inst 86 (1994) 717-722
78. Liljegren G., Holmberg L., Bergh J., et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 17 (1999) 2326-2333
79. Veronesi U., Luini A., Delvecchio M., et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 328 (1993) 1587-1591
80. Truong P., Bernstein V., Lesperance M., Speers C., and Olivotto N. Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer. Am J Surg 191 (2006) 749-755
81. Hughes K., Schnaper L., Berry D., et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351 (2004) 971-977
82. Veronesi U., Marubini E., Mariani L., et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12 (2001) 997-1003
83. Smith B., Gross C., Smith G., Galusha D., Bekelman J., and Haffty B. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 98 (2006) 681-690
84. Courdi A., Ortholan C., Hannoun-Levi J., et al. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol 79 (2006) 156-161
85. Munshi A., and Budrukkar A. Hypofractionated radiation therapy in breast cancer: a revolutionary breakthrough or a long way to go?. J Clin Oncol 25 (2007) 458-459
86. Ortholan C., Hannoun-Levi J., Ferrero J., Largillier R., and Courdi A. Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients. Int J Radiat Oncol Biol Phys 61 (2005) 154-162
87. Bartelink H., Horiot J., Poortmans P., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345 (2001) 1378-1387
88. Antonini N., Jones H., Horiot J., et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 82 (2007) 265-271
89. Bartelink H., Horiot J., Poortmans P., et al. Impact of radiation dose on local control, fibrosis and survival after breast conserving treatment: 10 years results of the EORTC trial 22881-10882. Breast Cancer Res Treat 100 (2006) S8
90. Overgaard M., Jensen M., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
91. Smith B., Haffty B., Hurria A., Galusha D., and Gross C. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol 24 (2006) 4901-4907
92. Lee J., Truong P., Kader H., Speers C., and Olivotto I. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer. Clin Oncol (R Coll Radiol) 17 (2005) 623-629
93. Recht A., Edge S., Solin L., et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1539-1569
94. Overgaard M., Jensen M., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
95. Harris J., Halpin-Murphy P., McNeese M., Mendenhall N., Morrow M., and Robert N. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 989-990
96. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30 (2001) 5-15
97. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
98. Crivellari D., Price K., Gelber R., et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 21 (2003) 4517-4523
99. Muss HB, Tu D, Ingle JN, et al. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. 29th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 14-17, 2006. Abstract 102.
100. Ragaz J., and Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 16 (1998) 2018-2024
101. Sheth H., Lord G., Tkaczuk K., et al. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. J Womens Health (Larchmt) 12 (2003) 799-808
102. Decensi A., Robertson C., Viale G., et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95 (2003) 779-790
103. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 15 (2006) S30-S40
104. Brufsky A, Dong M, Lund K, et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). 29th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 14-17, 2006. Abstract 5060.
105. Buzdar A., Howell A., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
106. Jenkins V., Shilling V., Fallowfield L., Howell A., and Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncol 13 (2004) 61-66
107. Bender CM, Sereika SM, Ryan CM, et al. Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer. 28th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8-11, 2005. Abstract 6074.
108. Jenkins V, Atkins L, Ambroisine L, Fleissig A, Fallowfield L, Howell A. Preliminary results from the IBIS II (prevention) cognitive sub-protocol. 29th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 14-17, 2006. Abstract 6074.
109. Giordano S., Duan Z., Kuo Y., Hortobagyi G., and Goodwin J. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24 (2006) 2750-2756
110. Elkin E., Hurria A., Mitra N., Schrag D., and Panageas K. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24 (2006) 2757-2764
111. Fisher B., Redmond C., Legaultpoisson S., et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast-cancer patients aged 50 years and older with tumors responsive to tamoxifen-results from the National Surgical Adjuvant Breast and Bowel Project-B-16. J Clin Oncol 8 (1990) 1005-1018
112. Albain K. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials. J Natl Cancer Inst 96 (2004) 1801-1804
113. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). 27th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8-11, 2004. Abstract 37.
114. Muss H., Woolf S., Berry D., et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293 (2005) 1073-1081
115. Fargeot P., Bonneterre J., Roche H., et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 22 (2004) 4622-4630
116. Du X., Osborne C., and Goodwin J. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20 (2002) 4636-4642
117. Goldhirsch A., Glick J., Gelber R., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
118. Jones S., Savin M., Holmes F., et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24 (2006) 5381-5387
119. Giordano S. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). Am Soc Proc Clin Oncol 24 (2006) (abstr 521).
120. Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 18 (2000) 1412-1422
121. De Maio E., Gravina A., Pacilio C., et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer 5 (2005) 30
122. Colleoni M., Price K., Castiglione-Gertsch M., Gelber R., Coates A., and Goldhirsch A. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet 354 (1999) 130-131
123. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
124. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
125. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
126. Aapro M., Cameron D., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
127. Smith T., Khatcheressian J., Lyman G., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
128. Touw I., and Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?. J Natl Cancer Inst 99 (2007) 183-186
129. Patt D., Duan Z., Fang S., Hortobagyi G., and Giordano S. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25 (2007) 3871-3876
130. Freyer G., Braud A., Chaibi P., et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol 17 (2006) 211-216
131. Khan S., Stewart A., and Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery 132 (2002) 620-626
132. Rapiti E., Verkooijen H., Vlastos G., et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 24 (2006) 2743-2749
133. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
134. Milla-Santos A., Milla L., Portella J., et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer-a prospective, randomized, phase III study. Am J Clin Oncol 26 (2003) 317-322
135. Mouridsen H., and Chaudri-Ross H. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist 9 (2004) 497-506
136. Christman K., Muss H., Case L., and Stanley V. Chemotherapy of metastatic breast cancer in the elderly-the Piedmont Oncology Association experience. JAMA 268 (1992) 57-62
137. Lichtman S., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 25 (2007) 1832-1843
138. Lichtman S., Wildiers H., Launay-Vacher V., Steer C., Chatelut E., and Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43 (2007) 14-34
139. Bajetta E., Procopio G., Celio L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23 (2005) 2155-2161
140. Del Mastro L., Perrone F., Repetto L., et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 16 (2005) 253-258
141. Feher O., Vodvarka P., Jassem J., et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 16 (2005) 899-908
142. ten Tije A., Verweij J., Carducci M., et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23 (2005) 1070-1077
143. Wildiers H., Highley M., de Bruijn E., and van Oosterom A. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinetics 42 (2003) 1213-1242
144. Dees E., O'Reilly S., Goodman S., et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18 (2000) 521-529
145. Hillner B., Ingle J., Chlebowski R., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
146. Tralongo P., Repetto L., Di Mari A., et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 67 (2004) 112-116
147. Giuliani R., Minisini A., Paesmans M., et al. Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol 22 (2004) (abstr 838).
148. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). 28th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 14-17, 2005. Abstract 3.
149. Skillings J., Johnson D., Miller K., et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizurnab (BV) with chemotherapy. J Clin Oncol 23 (2005) 196S